These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35730322)

  • 21. Data-Driven Soft Independent Modeling of Class Analogy in Paper Spray Ionization Mass Spectrometry-Based Metabolomics for Rapid Detection of Prostate Cancer.
    Pinto FG; Mahmud I; Rubio VY; Máquina ADV; Furtado Durans AF; Neto WB; Garrett TJ
    Anal Chem; 2022 Feb; 94(4):1925-1931. PubMed ID: 35060703
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Bruzzone C; Loizaga-Iriarte A; Sánchez-Mosquera P; Gil-Redondo R; Astobiza I; Diercks T; Cortazar AR; Ugalde-Olano A; Schäfer H; Blanco FJ; Unda M; Cannet C; Spraul M; Mato JM; Embade N; Carracedo A; Millet O
    J Proteome Res; 2020 Jun; 19(6):2419-2428. PubMed ID: 32380831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of the metabolic signatures of prostate cancer by mass spectrometry-based plasma and urine metabolomics analysis.
    Yu C; Niu L; Li L; Li T; Duan L; He Z; Zhao Y; Zou L; Wu X; Luo C
    Prostate; 2021 Dec; 81(16):1320-1328. PubMed ID: 34590739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NMR metabolomic profiles associated with long-term risk of prostate cancer.
    Lécuyer L; Victor Bala A; Demidem A; Rossary A; Bouchemal N; Triba MN; Galan P; Hercberg S; Partula V; Srour B; Latino-Martel P; Kesse-Guyot E; Druesne-Pecollo N; Vasson MP; Deschasaux-Tanguy M; Savarin P; Touvier M
    Metabolomics; 2021 Mar; 17(3):32. PubMed ID: 33704614
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolomics approaches and applications in prostate cancer research.
    Zhang A; Yan G; Han Y; Wang X
    Appl Biochem Biotechnol; 2014 Sep; 174(1):6-12. PubMed ID: 24838846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Large-scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels.
    Haldrup C; Lynnerup AS; Storebjerg TM; Vang S; Wild P; Visakorpi T; Arsov C; Schulz WA; Lindberg J; Grönberg H; Egevad L; Borre M; Ørntoft TF; Høyer S; Sørensen KD
    Mol Oncol; 2016 Jun; 10(6):825-37. PubMed ID: 26905753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis.
    Nørgaard M; Haldrup C; Storebjerg TM; Vestergaard EM; Wild PJ; Høyer S; Borre M; Ørntoft TF; Sørensen KD
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28930171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The applications of metabolomics in the molecular diagnostics of cancer.
    Cheung PK; Ma MH; Tse HF; Yeung KF; Tsang HF; Chu MKM; Kan CM; Cho WCS; Ng LBW; Chan LWC; Wong SCC
    Expert Rev Mol Diagn; 2019 Sep; 19(9):785-793. PubMed ID: 31414918
    [No Abstract]   [Full Text] [Related]  

  • 29. Altered staining patterns and expression level of Engrailed-2 in benign prostatic hyperplasia and prostate Cancer predict prostatic disease progression.
    Li Q; Shi Y; Sa R; Hao J; Hu J; Xiao M; Wang C; Yan L; Qiao B; Chen G
    BMC Cancer; 2020 Jun; 20(1):555. PubMed ID: 32539763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent progress and perspectives on prostate cancer biomarkers.
    Hatakeyama S; Yoneyama T; Tobisawa Y; Ohyama C
    Int J Clin Oncol; 2017 Apr; 22(2):214-221. PubMed ID: 27730440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nuclear magnetic resonance spectroscopy as a new approach for improvement of early diagnosis and risk stratification of prostate cancer.
    Yang B; Liao GQ; Wen XF; Chen WH; Cheng S; Stolzenburg JU; Ganzer R; Neuhaus J
    J Zhejiang Univ Sci B; 2017 Nov.; 18(11):921-933. PubMed ID: 29119730
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Huang J; Mondul AM; Weinstein SJ; Koutros S; Derkach A; Karoly E; Sampson JN; Moore SC; Berndt SI; Albanes D
    Br J Cancer; 2016 Oct; 115(9):1087-1095. PubMed ID: 27673363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapid Diagnosis of Prostate Cancer Disease Progression Using Paper Spray Ionization Mass Spectrometry.
    Mahmud I; Pinto FG; Rubio VY; Lee B; Pavlovich CP; Perera RJ; Garrett TJ
    Anal Chem; 2021 Jun; 93(22):7774-7780. PubMed ID: 34043339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NMR-based metabolomics analysis identifies discriminatory metabolic disturbances in tissue and biofluid samples for progressive prostate cancer.
    Zheng H; Dong B; Ning J; Shao X; Zhao L; Jiang Q; Ji H; Cai A; Xue W; Gao H
    Clin Chim Acta; 2020 Feb; 501():241-251. PubMed ID: 31758937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolomic signatures of aggressive prostate cancer.
    McDunn JE; Li Z; Adam KP; Neri BP; Wolfert RL; Milburn MV; Lotan Y; Wheeler TM
    Prostate; 2013 Oct; 73(14):1547-60. PubMed ID: 23824564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of a biomarker panel for improvement of prostate cancer diagnosis by volatile metabolic profiling of urine.
    Lima AR; Pinto J; Azevedo AI; Barros-Silva D; Jerónimo C; Henrique R; de Lourdes Bastos M; Guedes de Pinho P; Carvalho M
    Br J Cancer; 2019 Nov; 121(10):857-868. PubMed ID: 31588123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PSMA/PSA ratio evaluated by immunohistochemistry may improve diagnosis of prostate cancer.
    Jemaa AB; Bouraoui Y; Sallami S; Banasr A; Nouira Y; Oueslati R
    J Immunoassay Immunochem; 2014; 35(1):48-59. PubMed ID: 24063616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation.
    Ouellet V; Aprikian A; Bergeron A; Brimo F; Bristow RG; Chevalier S; Drachenberg D; Fazli L; Fleshner NE; Gleave M; Karakiewicz P; Klotz L; Lacombe L; Lattouf JB; van der Kwast T; Squire JA; Latour M; Trudel D; Mes-Masson AM; Saad F
    BMC Urol; 2018 Sep; 18(1):78. PubMed ID: 30200929
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biomarkers in localized prostate cancer.
    Ferro M; Buonerba C; Terracciano D; Lucarelli G; Cosimato V; Bottero D; Deliu VM; Ditonno P; Perdonà S; Autorino R; Coman I; De Placido S; Di Lorenzo G; De Cobelli O
    Future Oncol; 2016 Feb; 12(3):399-411. PubMed ID: 26768791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence-based medical perspectives: the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression of prostate cancer.
    Lieberman R
    Am J Ther; 2004; 11(6):501-6. PubMed ID: 15543092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.